Lexaria Bioscience Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Lexaria Bioscience Corp. (LEXX) - Annual data in millions USD
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingDec 2025Aug 2024Aug 2023Aug 2022Aug 2021
Operating Activities
Net Income-11.91-5.80-6.66-7.27-4.03
Depreciation & Amortization0.090.080.190.100.15
Stock Based Compensation0.860.490.170.751.28
Change in Working Capital0.200.110.14-0.350.06
Change in Accounts Receivable-0.21-0.040.03-0.140.19
Change in Inventory0.000.000.040.000.10
Change in Accounts Payable0.000.830.090.050.01
Change in Other Working Capital0.410.04-0.011.24-0.19
Other Operating Activities0.320.04-0.051.24-0.15
Net Cash from Operating Activities-10.45-4.96-5.88-4.88-3.99
Investing Activities
Capital Expenditures-0.02-0.19-0.03-0.180.00
Sales/Maturities of Investments0.00-0.15-0.14-0.13-0.08
Other Investing Activities-0.220.000.000.000.00
Net Cash from Investing Activities-0.24-0.19-0.17-0.180.19
Financing Activities
Debt Repayment0.000.000.00-0.040.00
Common Stock Issued6.054.211.590.0013.49
Net Cash from Financing Activities6.0510.321.59-0.0413.42
Summary
Effect of Forex Changes on Cash-0.05-0.020.000.000.00
Net Change in Cash-4.705.17-4.46-5.109.62
Cash at Beginning of Period6.501.355.8110.920.00
Cash at End of Period1.806.501.355.810.00
Free Cash Flow-10.48-5.15-5.91-5.06-3.99
Supplemental Disclosures
Income Taxes Paid0.000.000.010.00-0.02